Organization (Other)
Children Hospital and Institute of Child Health, Lahore
ClinicalTrials.gov lists Children Hospital and Institute of Child Health, Lahore as lead sponsor of 10 trials. It has 10 active development programs and 3 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 1 registered with a 2026 start date. The dashed outline is the pace from the 1 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 2.0 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers Children Hospital and Institute of Child Health, Lahore: 10 lead-sponsored trials and 0 legal-entity registrations.
Disease areas (17)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Cholelithiasis | 1 |
| Cicatrix | 1 |
| Deglutition Disorders | 1 |
| Diabetes Mellitus | 1 |
| Diabetic Foot | 1 |
Showing 5 of 17 disease areas.
Trials by start year as sponsor or collaborator (6)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2025 | 1 |
| 2024 | 1 |
| 2023 | 3 |
| 2022 | 4 |
| 2021 | 1 |
Recruitment duration, a model prediction: none of the 10 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (10)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Permethrin Cream 5% | Scabies | Phase 2 | 1 |
| Ivermectin 200 µg/kg | Scabies | Phase 2 | 1 |
| Ivermectin 200 µg/kg | Mite Infestations | Phase 2 | 1 |
| Permethrin Cream 5% | Mite Infestations | Phase 2 | 1 |
| Rivaroxaban | Venous Thrombosis | Phase 1 | 1 |
Showing 5 of 10 active programs.
Approved assets (3)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Silver Nitrate | 1 |
| Sodium warfarin | 1 |
| Rivaroxaban | 1 |
Journals published in (8)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Annals of gastroenterology | 1 |
| Current gastroenterology reports | 1 |
| Endoscopy | 1 |
| Journal of pediatric gastroenterology and nutrition | 1 |
| Revista de gastroenterologia de Mexico | 1 |
Showing 5 of 8 journals.
Latest dated events (11)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-08 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-05-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2024-04-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2023-07-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2023-04-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 11 events.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, sponsor delivery record, us granted patents, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, organization relationships, clia clinical laboratory certificates, biomarker capability evidence, and biomarkers this organization publishes on.